Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-06-30 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东执行事务合伙人变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a change in the executing partner of a shareholder holding more than 5% of the company's shares. It details the change in partnership roles within a limited partnership that holds shares in the company. There is no financial data, no report attached or referenced, and no mention of financial results or regulatory filings beyond this ownership and management change. The content fits the category of Major Shareholding Notification, as it concerns changes related to a significant shareholder's internal structure, although it explicitly states no change in shareholding percentage. Given the focus on a shareholder with over 5% ownership and changes in partnership roles, the best fitting category is Major Shareholding Notification (MRQ). The document length is short and focused on this specific change, confirming this classification.
2020-06-30 Chinese
第一期员工持股计划第一次持有人会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the first meeting of holders of an employee stock ownership plan (ESOP) for Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, voting results, and decisions such as the establishment of a management committee for the ESOP and authorization of the committee to handle related matters. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal announcement of meeting resolutions related to employee shareholding plan governance. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about governance and shareholder meeting outcomes but not a full governance report or management change announcement. The document length is short (2118 characters), and it is not an announcement of a report publication but a standalone announcement of meeting resolutions.
2020-06-30 Chinese
公司债券2020年跟踪评级报告
Regulatory Filings
2020-06-24 Chinese
独立董事关于第二届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent opinion from independent directors regarding matters discussed at the 21st meeting of the second board of directors. It discusses approval and opinions on related party transactions and equity transfer of a subsidiary. The content focuses on governance and board-level decisions rather than financial results or regulatory filings. The document length is short (1036 characters) and it is a formal opinion related to board meeting matters, not a full report or announcement of voting results. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management.
2020-06-22 Chinese
独立董事关于第二届董事会第二十一次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is titled as an opinion from independent directors regarding matters to be discussed at the 21st meeting of the second board of directors. It references regulatory guidelines related to independent directors and board meeting procedures. The content focuses on pre-approval opinions on specific board agenda items, such as increasing daily related-party transaction limits and transferring part of a subsidiary's equity. There is no financial data, earnings information, or report publication. The document is clearly related to board/management information, specifically the independent directors' opinions on board meeting matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so RNS or RPA are not appropriate.
2020-06-22 Chinese
中信证券股份有限公司关于公司转让控股子公司深圳华大因源医药科技有限公司部分股权暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of partial equity of a controlling subsidiary (Shenzhen Huada Yinyuan Pharmaceutical Technology Co., Ltd.) by Shenzhen Huada Gene Co., Ltd. It includes extensive information about the transaction parties, their financials, the transaction pricing, agreements, and the impact on the listed company. The document references regulatory rules such as the Shenzhen Stock Exchange GEM Listing Rules and includes independent directors' opinions and board meeting approvals. It is a comprehensive disclosure of a related-party transaction involving equity transfer and associated agreements. This type of document is typical of a Capital/Financing Update (CAP) filing, as it details fundraising, equity transfer, and capital structure changes. It is not an annual or interim report, audit report, earnings release, or other categories. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2020-06-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.